A Case Report of Malaria-associated Secondary Hemophagocytic Lymphohistiocytosis and a Review of the Literature

Xiao Zhou
Beijing Friendship Hospital

Meili Duan (✉ 18618334341@163.com)

Case report

Keywords: Fever, malaria, hemophagocytic lymphohistiocytosis, secondary

DOI: https://doi.org/10.21203/rs.3.rs-33600/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Malaria-associated secondary hemophagocytic lymphohistiocytosis (HLH) is rare. Moreover, the literature on malaria-associated HLH is sparse, and there are no similar cases reported in China.

**Case presentation:** We report a case of a 29-year-old young woman with unexplained intermittent fever who was admitted to our hospital due to an unclear diagnosis. The patient concealed her history of travel to Nigeria and Dubai before onset. We made a diagnosis of malaria-associated secondary HLH. The treatment strategy for the patient included treatment of the inciting factor (artemether for 9 days followed by artemisinin for 5 days), the use of immunosuppressants (steroids, intravenous immunoglobulin) and supportive care. The patient was discharged in normal physical condition after 25 days of intensive care. No relapses were documented on follow-up at six months and 1 year.

**Conclusion:** Early diagnosis of the primary disease along with timely intervention and a multidisciplinary approach can help patients achieve a satisfactory outcome.

Background

HLH is a systemic disorder caused by immune dysregulation that occurs in primary and secondary forms. Secondary HLH refers to cases caused by infections, malignancy and autoimmune diseases. HLH secondary to infections can occur with viral, bacterial, fungal or parasitic infections\footnote{1}. Malaria is rarely reported to cause HLH. We report a case of a 29-year-old young woman with fever, hepatosplenomegaly, pancytopenia, high serum ferritin, hypertriglyceridemia, hypofibrinogenemia and bone marrow hemophagocytosis, consistent with hemophagocytic syndrome. Plasmodium falciparum (P. falciparum) was identified on a peripheral blood smear. Rapid recovery was observed after treatment with antimalarial medications, immunomodulatory therapy and supportive care.

Case presentation

A 29-year-old young woman was admitted to the hospital due to intermittent fever for 12 days. The patient had an unexplained fever (Tmax 41°C), chills and anorexia after a trip to Nigeria and Dubai in September 2018. However, the patient concealed her travel history while visiting the local hospital. She was diagnosed with pneumonia and received antibiotic treatment. With poor response to antibacterial treatment, the patient developed nausea, vomiting, upper abdominal pain, respiratory distress and oliguria. Further investigations showed negativity for Epstein–Barr virus (EBV) DNA but positivity for EBV-IgM. Bone marrow biopsy revealed hemophagocytosis. The patient was diagnosed suspiciously with EBV-related HLH, and she was transferred to our hospital for emergency treatment.

We obtained a detailed medical history from the patient and learned about her history of travel. Physical examination revealed a blood pressure of 105/64 mmHg, wet rales in the lower lung and upper abdominal tenderness. Blood tests showed cytopenias, increased liver transaminases, increased bilirubin, hypertriglyceridemia, increased serum ferritin and splenomegaly on abdominal ultrasonography and CT.
(computed tomography) (Figure 1). Tests for EBV and cytomegalovirus DNA were negative. There was no
evidence of a tumor. A peripheral blood smear showed P. falciparum (Figure 2a), which was determined to
have a 3D7 genotype. Bone marrow aspiration showed the presence of hemophagocytosis (Figure 3),
with a soluble CD25 (sCD25) level of 21,574 pg/ml and negative results for natural killer cell (NK cell)
activity. A final diagnosis of malaria-associated secondary HLH was made.

The treatment regimen for malaria included artemether at 80 mg q12h for 4 days and then 80 mg qd for 5
days, which was changed to dihydroartemisinin and piperaquine phosphate 2 tablets qd for 5 days. At
the same time, the patient received treatment with methylprednisolone 80 mg qd for 4 days. Since we
considered the HLH to be secondary to malaria, we treated the primary disease and used intravenous
immunoglobulin (IVIG) for 5 days (total dose of 2 g/kg). After 7 days of treatment, no P. falciparum was
found in the peripheral blood smear (Figure 2b), and tests for malarial antigens were negative. The
patient's condition improved gradually, and her clinical and laboratory manifestations were normalized
(Table 1).

Subsequently, the patient manifested multiorgan dysfunction. She exhibited acute kidney injury (creatine
569 µmol/l with oliguria), acute liver injury, acute respiratory distress syndrome (P/F 100 mmHg) and
coagulopathy and was treated with continuous renal replacement therapy, high-flow nasal cannula
oxygen therapy (HFNC), blood transfusion and nutritional support in the critical care unit. After 7 days of
organ support treatment, the patient's respiratory and renal function recovered to normal, and her liver-
enzyme and bilirubin levels decreased. She was discharged in normal physical condition after 25 days.
No relapses were documented at her six-month and 1-year follow-ups.

Discussion

Malaria is a mosquito-borne infectious disease that is caused by a parasitic protozoan of the genus
Plasmodium and has diverse clinical manifestations\(^2\). The epidemiological history is important for
diagnosis. Therefore, we should solicit a thorough and detailed medical history. The diagnosis of malaria
was based on a peripheral blood smear and/or rapid diagnostic tests for malarial antigens. Artemisinin is
mainly used in the treatment of malaria. Our patient was treated with artemether first because the effect
of artemether is 6 times more potent that of artemisinin. Then, she subsequently took oral
dihydroartemisinin and piperaquine phosphate. There are also reports of oral doxycycline treatment in the
literature.

HLH, a life-threatening disease associated with excessive stimulation of tissue macrophages\(^3\), occurs in
primary and secondary forms. Primary HLH is mostly recognized in childhood, whereas the secondary
form can occur at any age. Secondary HLH refers to cases caused by infections, malignancy and
autoimmune diseases. HLH secondary to infections can occur with viral, bacterial, fungal or parasitic
infections; viral infections, especially those caused by EBV, are the most common\(^4\). The clinical and
laboratory manifestations of HLH include fever, splenomegaly, neurologic dysfunction, coagulopathy,
liver dysfunction, cytopenias, hypertriglyceridemia, hyperferritinemia, hemophagocytosis, and diminished NK-cell activity. In fact, the clinical manifestations of HLH lack specificity. The severity is related to the levels of immune cell activation and cytokines. Currently, we make the diagnosis based on HLH-2004 criteria\[^5\] (Table 2). Hemophagocytosis cannot be used as a necessary condition to exclude or diagnose HLH. The sensitivity of hemophagocytosis in the diagnosis of HLH is approximately 60%. HLH cannot be excluded in the absence of hemophagocytosis. The sensitivity of ferritin > 500 µg/L in the diagnosis of HLH is 84%. Serum ferritin < 500 µg/L has a negative evaluative significance for the diagnosis of HLH. NK-cell activity is a landmark diagnostic indicator that is irreversible in primary HLH but can be recovered in secondary HLH. The reference range varies depending on the detection method. sCD25 is the most useful marker of inflammation, which reflects the excessive immune activation status of patients. The literature reports that elevated sCD25 in children has a sensitivity of 76.2% and a specificity of 98.2% for the diagnosis of HLH\[^6\]. The treatment strategy for secondary HLH includes supportive care, treatment of inciting factors and the use of immunosuppressants (steroids, IVIG and other immunosuppressive drugs).

Malaria as a cause of secondary HLH is rare. We reviewed the related literature, and fewer than 20 cases have been reported\[^7\]–[21]. There are no similar cases reported in China. The reason is that on the one hand, China is not a malaria-endemic area, and on the other hand, some cases have not been recognized and diagnosed. The types of malarial parasites that cause secondary HLH are P. falciparum and P. vivax\[^8\][13], with P. falciparum accounting for most of these cases. The pathogenesis is not yet clear but may be related to immune dysfunction caused by falciparum malaria. Whether the pathogenic mechanisms of the different types of Plasmodium are different still needs further study.

In this case, the patient had fever and gastrointestinal symptoms, such as fatigue, anorexia, nausea, and vomiting, but no enlarged lymph nodes, rash, bleeding or neurologic dysfunction. Although NK-cell activity was negative, the diagnosis of HLH clearly met seven out of the eight HLH-2004 criteria. However, in most cases reported in the literature, NK-cell activity and soluble CD25 antigen levels were not available. Thanks to the new diagnostic markers, we made the diagnosis in time. Meanwhile, intensive care unit intervention played a valuable role in the patient's recovery during the course. No death due to malaria-associated HLH has been reported. Our patient also had a good prognosis.

**Conclusion**

In conclusion, malaria-associated secondary HLH is rare. If the patient has fever, splenomegaly and an elevated ferritin level, HLH should be highly suspected, and relevant examinations should be conducted. Early diagnosis of the primary disease along with timely intervention and a multidisciplinary approach can help patients achieve a satisfactory outcome.

**Abbreviations**

HLH
hemophagocytic lymphohistiocytosis
P.falciparum
Plasmodium falciparum
EBV
Epstein–Barr virus
CT
computer tomography
sCD25
Soluble CD25
NK cell
natural killer cell
IVIG
intravenous immunoglobulin
HFNC
high-flow nasal cannula oxygen therapy
P. vivax
Plasmodium vivax

Declarations

- Ethics approval and consent to participate

This study was approved by the Hospital Ethics Committee, No. 2018-P2-190-01. This study obtained consent for publication from the patient. The participant consent was written.

(Picture seen in the appendix)

- Consent for publication

All of the authors have consented to the publication of this study.

- Availability of data and material

Not applicable.

- Competing interests

The authors declare that they have no competing interests.

- Funding

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding, ZYLX201802. The funding body provided support for the writing of the manuscript.

- Authors' contributions
MLD developed the treatment strategies for the patient. XZ administered the treatments and read the literature. XZ was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

- Acknowledgments

The authors express special thanks to Dr. Ji Xiaojun, Dr. Liu Jingfeng, Dr. Wang Lei and Dr. Jianing Chen, who guided this work.

References

1. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA. Bosch X. Adult haemophagocytic syndrome. Lancet. 2014. doi:10.1016/S0140-6736(13)61048-X.

2. Weeratunga P, Rathnayake G, Sivashangar A, Karunanayake P, Gnanathasan A, Chang TP. Plasmodium Falciparum and Mycoplasma Pneumoniae Co-Infection Presenting With Cerebral Malaria Manifesting Orofacial Dyskinesia and Haemophagocytic Lymphohistiocytosis. Malar J. 2016; doi: 10.1186/s12936-016-1517-x.

3. Klein E, Ronez E. Peripheral hemophagocytosis in malaria infection. Blood. 2012; doi:10.1182/blood-2011-02-336420.

4. Muthu V, Dhooria S, Sehgal IS, Agarwal R, Behera D, Varma N. Malaria-associated secondary haemophagocytic lymphohistiocytosis: Report of two cases & a review of literature. Indian J Med Res. 2017. doi:10.4103/ijmr.IJMR_740_15.

5. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007. doi:10.1002/pbc.21039.

6. Yingchao Wang D, Liu G, Zhu C, Yin G, Sheng. Xiaoming Zhao. Significance of Soluble CD163 and Soluble CD25 in Diagnosis and Treatment of Children With Hemophagocytic Lymphohistiocytosis. Zhonghua Er. Ke Za Zhi. 2015; 53(11):824–9.

7. Bhagat M, Kanhere S, Kadakia P, Phadke V, George R, Chaudhari K. Haemophagocytic, Lymphohistiocytosis. A Cause of Unresponsive Malaria in a 5-year-old Girl. Paediatr Int Child Health. 2015. doi:10.1080/20469047.2015.1109227.

8. Amireh S, Shaaban H, Guron G. Severe Plasmodium vivax cerebral malaria complicated by hemophagocytic lymphohistiocytosis treated with artesunate and doxycycline. Hematol Oncol Stem Cell Ther. 2018. doi:10.1016/j.hemonc.2016.06.001.

9. Ullah W, Abdullah HM, Qadir S, Shahzad MA. Haemophagocytic lymphohistiocytosis (HLH): a rare but potentially fatal association with Plasmodium vivax malaria. BMJ Case Rep. 2016; doi: 10.1136/bcr-2016-215366.

10. Bhagat M, Kanhere S, Kadakia Affiliation When The Manuscript Was Written Department Of Paediatrics K J Somaiya Medical College And Hospital Mumbai India P, Phadke V, George R,
Chaudhari K. Haemophagocytic lymphohistiocytosis: a cause of unresponsive malaria in a 5-year-old girl. Paediatr Int Child Health. 2014. doi:10.1179/2046905514Y.0000000163. Online ahead of print.

11. Trifi A, Terra A, Abdelatif S, Daly F, Oueslati M, Laamari L, Kallel K, Ben Lakhal S, Tiouiri H. Chaker E. Haemophagocytic lymphohistiocytosis syndrome - related to severe malaria: rare association. Tunis Med. 2014;92(7):515–6.

12. Pahwa R, Singh T, Khurana N. Hemophagocytic syndrome in malaria and kala-azar. Indian J Pathol Microbiol. 2004;47(3):348–50.

13. Bae E, Jang S, Park CJ, Chi HS. Plasmodium vivax malaria-associated hemophagocytic lymphohistiocytosis in a young man with pancytopenia and fever. Ann Hematol. 2011. doi:10.1007/s00277-010-1042-x.

14. Santos JA, Neves JF, Venâncio P, Gouveia C, Varandas L. Hemophagocytic lymphohistiocytosis secondary to Falciparum malaria in a 5 year-old boy. Ann Hematol. 2015. doi:10.1007/s00277-014-2118-9.

15. Selvarajan D, Sundaravel S, Alagusundaramoorthy SS, Jacob A. Hemophagocytic lymphohistiocytosis with concurrent malarial infection. BMJ. Case Rep. 2017. doi:10.1136/bcr-2017-221159.

16. Harioly Nirina MOM, Raheritiana TM, Harioly Nirina MOJ, Rasolonjatovo AS, Rakoto Alson AO. Rasamindrakotroka A. Hemophagocytic lymphohistiocytosis associated with Plasmodium falciparum. Med Mal Infect. 2017. doi:10.1016/j.medmal.2017.07.005.

17. Niang A, Niang SE, Ka el HF, Ka MM, Diouf B. Collapsing glomerulopathy and haemophagocytic syndrome related to malaria: a case report. Nephrol Dial Transplant. 2008. doi:10.1093/ndt/gfn427.

18. Pothapregada S, Kamalakannan B. Hemophagocytic syndrome in Plasmodium vivax malaria. J Vector Borne Dis. 2014;51(2):144–6.

19. Ohnishi K, Mitsui K, Komiya N, Iwasaki N, Akashi A, Hamabe Y. Clinical case report: falciparum malaria with hemophagocytic syndrome. Am J Trop Med Hyg. 2007;76(6):1016–8.

20. Vinoth PN, Thomas KA, Selvan SM, Suman DF, Scott JX. Hemophagocytic syndrome associated with Plasmodium falciparum infection. Indian J Pathol Microbiol. 2011. doi:10.4103/0377-4929.85105.

21. Tanwar GS, Lahoti A, Tanwar P, Agrawal R, Khatri PC, Kochar DK. Hemophagocytic syndrome associated with severe Plasmodium vivax malaria in a child in Bikaner (northwestern India). J Vector Borne Dis. 2013;50(4):318–20.

Tables
Table 1 The change in clinical and laboratory manifestations before and after treatment

|                          | Reference range | Before treatment | 7 days after treatment | 14 days after treatment |
|--------------------------|-----------------|------------------|------------------------|------------------------|
| **Temppreture (°C)**     | 36-37           | Tmax39.8          | No fever               | No fever               |
| **White blood cells (x10^9/L)** | 3.50-9.50      | 2.88             | 3.78                   | 4.33                   |
| **Neutrophils (x10^9/L)** | 1.8-6.3         | 1.31             | 2.15                   | 2.00                   |
| **Hemoglobin (g/L)**     | 115-150         | 49               | 108                    | 93                     |
| **Platelet count (x10^9/L)** | 125-350        | 50               | 112                    | 151                    |
| **Reticulocytes (x10^12/L)** | 0.0140-0.0900  | 0.1443           | 0.2269                 | 0.0902                 |
| **IB (umol/L)**          | 0.00-12.00      | 15.44            | 16.09                  | 8.59                   |
| **TG (mmol/L)**          | 0.57-1.70       | 2.45             | 2.42                   | 2.23                   |
| **Ferritin (ng/ml)**     | 11.00-306.00    | 1989.00          | 1730                   | 1516                   |
| **Fbg (ng/ml)**          | 1.70-4.00       | 1.41             | 1.31                   | 1.63                   |
| **NK-cell activity**     | negative        |                  | -                      |                        |
| **sCD25 (pg/ml)**        |                 | 21574            |                        | 4775                   |
| **Speen ultrasonography**|                 | 14.2             |                        | -                      |
|                          | length 8.5±1.0cm|                  |                        |                        |
|                          | thickness 2.8±0.5cm |              |                        | 3.4                   |
Table 2 Diagnosis of HLH-2004 criteria

| The diagnosis HLH can be established if either condition 1 or condition 2 below is fulfilled. |
|---|
| (1) A molecular diagnosis consistent with HLH |
| (2) Diagnostic criteria for HLH fulfilled (five out of the eight criteria below) |
| (A) Initial diagnostic criteria (to be evaluated in all patients with HLH) |
| Fever |
| Splenomegaly |
| Cytopenias (affecting ≥2 of 3 lineages in the peripheral blood): |
| Hemoglobin <90 g/L (in infants <4 weeks: hemoglobin <100 g/L) |
| Platelets <100 × 10⁹/L |
| Neutrophils <1.0 × 10⁹/L |
| Hypertriglyceridemia and/or hypofibrinogenemia: |
| Fasting triglycerides ≥3.0 mmol/L (i.e., ≥265 mg/dl) |
| Fibrinogen ≤1.5 g/L |
| Hemophagocytosis in bone marrow or spleen or lymph nodes |
| No evidence of malignancy |
| (B) New diagnostic criteria |
| Low or absent NK-cell activity (according to local laboratory reference) |
| Ferritin ≥500 μg/L |
| Soluble CD25 (i.e., soluble IL-2 receptor) ≥2,400 U/ml |

Figures
Figure 1 Abdominal CT showed hepatosplenomegaly.

Figure 2 Peripheral blood smear.
Figure 2a (left) showed hemophagocytes with malarial gametocytes (yellow arrow).
Figure 2b (right) showed that no Plasmodium was found.
Figure 3 Bone marrow aspiration showed the presence of hemophagocytosis (green arrow).

Figure 3

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Ethicsapproval2.jpg
- Ethicsapproval1.jpg